Skip to main content
Clinical Trials/NCT01120977
NCT01120977CompletedNot Applicable

Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study

University of Aarhus1 site in 1 country150 target enrollmentStarted: May 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
150
Locations
1

Study Overview

Brief Summary

The treatment of Growth Hormone deficiency (GHD) patients with GH, often induce fluid retention; this effect is dose dependent and temporary. The symptoms are swelling of soft tissue and joint stiffness. The objective of this study is to create bioelectric impedance/arm muscle area (BIA/AMA) reference data, as a measurement of hydration status, of healthy persons of both genders in the age 20-70 years.

Detailed Description

The treatment of Growth Hormone deficiency (GHD) patients with GH, has since 1994 been approved in several countries. The approval is based on studies that show positive effect on body composition, physiology, lipid profile, bone density and life quality. One often observed side effect is fluid retention; this effect is dose dependent and temporary. The symptoms are swelling of soft tissue and joint stiffness.

By comparing the body bioelectric impedance (BIA) with an Arm Muscle Area (AMA) measurement, it is possible to determine the hydrations status of a person. This measurement is a simple and non invasive method to evaluate the GH dosages applied in the treatment of GHD persons.

The objective of this study is to create BIA/AMA reference data of healthy persons of both genders in the age 20-70 years.

Study Design

Study Type
Observational
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
20 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy persons,
  • Age 20- 70 years.

Exclusion Criteria

  • Cardiac implanter (pacemaker),
  • Heart insufficiency, chronic venuos insufficiency,
  • Use of diuretics, desmopressin, neuroleptica, antidepressants, corticosteroids, fludrocotidon,
  • Obesity (BMI > 30),
  • Knowledge of changes in electrolyte or water homeostasis.

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials